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Introduction
P21-activated kinase (PAK) function impacts a plethora of 
cellular processes, including cell migration, cell survival, em-
bryonic development, and transcriptional regulation (Qu et al., 
2003; Li and Minden, 2005; Bompard et al., 2010; Li et al., 
2012). Indeed, there is much pharmaceutical and academic 
interest in developing PAK-specific inhibitors (Murray et al., 
2010; Zhang et al., 2012).
PAKs are serine/threonine kinases best known as Rac and 
Cdc42 effector proteins. The mammalian family of PAK pro-
teins is subdivided into two groups: group I PAKs (PAK1–3) 
and group II PAKs (PAK4–6; Dart and Wells, 2013). Function-
ally, group II PAKs are thought to preferentially interact with 
Cdc42 and related Rho family small GTPases (Abo et al., 1998; 
Wu and Frost, 2006; Shepelev and Korobko, 2012). However, 
although interaction with GTPases can lead to increased group 
I PAK activation (Eswaran et al., 2008), the part played by the 
Rho GTPases in activating group II PAKs has been the subject 
of much debate (Baskaran et al., 2012; Ha et al., 2012; Wang et 
al., 2013), and the role of other Cdc42-related family members 
has not been elucidated.
Of the group II PAKs, PAK4 has been specifically asso-
ciated with several features of tumorigenesis, such as anchor-
age-independent growth, increased cell survival, migration, and 
invasion (Gnesutta et al., 2001; Callow et al., 2002; Siu et al., 
2010; Rafn et al., 2012; Park et al., 2013; Tabusa et al., 2013). 
There is a strong correlation between PAK4 and breast can-
cer; PAK4 is up-regulated at the protein level in several breast 
cancer cell lines in addition to primary human breast and rat 
mammary tumor samples (Callow et al., 2002; Liu et al., 2008, 
2010). Furthermore, the chromosomal region 19q13.2, in which 
PAK4 resides, is often amplified at a high frequency in aggres-
sive breast cancers with basal-like features (Yu et al., 2009).
Most known PAK4 functions depend on kinase activity, 
and so far, kinase-independent events have not been associ-
ated with cell adhesion and migration (Dart and Wells, 2013). 
Moreover, a mechanistic basis of PAK4 function within breast 
cancer cells remains to be elucidated. It had been previously 
established in prostate cancer that PAK4 was essential for cell 
migration via phosphorylation of LIMK1 in mesenchymal-like 
cells (Ahmed et al., 2008; Whale et al., 2013), but no func-
tional link to cell adhesion dynamics was reported. In contrast, 
in colony-forming cells, PAK4 promoted the disassembly of 
focal adhesions via phosphorylation of paxillin at serine 272 
(S272; Wells et al., 2010).
Although the molecular processes that drive focal adhe-
sion formation have been extensively characterized, the process 
of adhesion disassembly is less well defined (Wehrle-Haller, 
2012). However, disassembly is likely to involve spatiotempo-
P21-activated kinase 4 (PAK4) is a Cdc42 effector protein thought to regulate cell adhesion disassembly in a kinase-de-
pendent manner. We found that PAK4 expression is significantly higher in high-grade human breast cancer patient 
samples, whereas depletion of PAK4 modifies cell adhesion dynamics of breast cancer cells. Surprisingly, systematic 
analysis of PAK4 functionality revealed that PAK4-driven adhesion turnover is neither dependent on Cdc42 binding nor 
kinase activity. Rather, reduced expression of PAK4 leads to a concomitant loss of RhoU expression. We report that RhoU 
is targeted for ubiquitination by the Rab40A–Cullin 5 complex and demonstrate that PAK4 protects RhoU from ubiquiti-
nation in a kinase-independent manner. Overexpression of RhoU rescues the PAK4 depletion phenotype, whereas loss 
of RhoU expression reduces cell adhesion turnover and migration. These data support a new kinase-independent mech-
anism for PAK4 function, where an important role of PAK4 in cellular adhesions is to stabilize RhoU protein levels. Thus, 
PAK4 and RhoU cooperate to drive adhesion turnover and promote cell migration.
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ral regulation of the Rho family GTPases. Interestingly, RhoU 
is thought to modulate focal adhesion dynamics in HeLa cells 
(Chuang et al., 2007; Ory et al., 2007). Unlike conventional GT-
Pases, RhoU exhibits extremely high intrinsic guanine nucleo-
tide exchange activity and is rendered largely in the GTP-loaded 
conformation. Thus, regulation of RhoU activity is thought to 
be distinct from that of conventional Rho GTPases (Saras et al., 
2004; Shutes et al., 2004).
Results
PAK4 expression is correlated with breast 
cancer cell migration
Recent studies have suggested that PAK4 expression may be in-
dicative of a poorer prognosis in cancer (Siu et al., 2010; Zhang 
et al., 2011). We examined the expression level of PAK4 in 300 
human breast cancer tissue samples with normal controls. Both 
weak and strong cytoplasmic PAK4 staining of epithelial cells 
was observed (Fig. 1 A). Importantly, a significantly higher level 
of PAK4 expression was found in the more severe grade of in-
vasive breast carcinomas (Fig. 1 A). To further examine the role 
of PAK4 in breast cancer, we generated stable MDA-MB-231 
cell lines expressing control nontargeting or one of two inde-
pendent PAK4-specific shRNA. PAK4 protein levels were re-
duced by >50% in the cell lines stably expressing PAK4 shRNA 
(Oligo1 and Oligo3) without detectably changing the levels 
of the group I PAK, PAK1, and another group II PAK, PAK6 
(Fig. 1 B), or phospho-PAK6 (S560) levels (Fig. 1 B). Loss of 
PAK4 expression correlated with an increase in the adhesion 
of MDA-MB-231 cells to a fibronectin substratum (Fig. 1 C) 
with a concomitant increase in the number and length of focal 
adhesions compared with control cells (Fig. 1 D), a phenotype 
replicated in MCF-7 cells (Fig. S1, A–C). In contrast, depletion 
of PAK1/PAK2 expression (Fig. S1 D) did not phenocopy the 
PAK4-depleted cells (Fig. S1 E). Indeed, reduced expression 
of either protein had no effect on focal adhesion number (Fig. 
S1 E). Thus, in breast cancer cells, the PAK4 adhesion pheno-
type dominates (Wells et al., 2010). We have previously shown 
using interference reflection microscopy that this PAK4-medi-
ated change in adhesion dynamics is a direct consequence of 
reduced cell substratum adhesion disassembly (Wells et al., 
2010). In breast cancer cells, we were also able to detect en-
dogenous PAK4 in a complex with paxillin and vinculin (Fig. 
S2 A). Control of cellular adhesion is frequently related to cell 
migration, and we found that knockdown of PAK4 significantly 
attenuated migration potential (MDA-MB-231 [Fig.  1 E] and 
MCF-7 [Fig. S1 F]), demonstrating that PAK4 expression is 
necessary for optimal breast cancer cell motility.
PAK4-dependent cell adhesion does not 
require Cdc42
Our data clearly demonstrate that PAK4 drives breast cancer 
cell migration. However, a requirement for kinase activity and 
regulation of PAK4 activity remains to be defined. PAK4 pref-
erentially binds to GTP-bound Cdc42 (Abo et al., 1998), which 
can activate PAK4 (Baskaran et al., 2012). Moreover, Cdc42 
binding is necessary for full hepatocyte growth factor–mediated 
motility of PC3 prostate cancer cells (Whale et al., 2013). Yet, 
both PAK4r (shRNA-resistant PAK4; Whale et al., 2013) and 
PAK4 (H19, 22L)r (a Cdc42 binding–deficient mutant; Whale 
et al., 2013) were able to rescue the adhesion of PAK4 knock-
down cells to control levels (Fig. 2, A and B), demonstrating 
that an interaction between Cdc42 and PAK4 is not required. 
We therefore sought to identify whether another Rho GTPase 
might regulate PAK4 function. PAK4 did not bind to Rac1, 
RhoG, RhoA, RhoJ, or RhoQ (Fig. S2 B). As expected, PAK4 
bound to Cdc42 but also interacted with RhoU (Fig. 2 C) and 
RhoV (Fig. S2 B). Because RhoU has already been shown to 
localize to focal adhesions (Chuang et al., 2007; Ory et al., 
2007), we chose to focus our attention on this particular small 
GTPase. RhoU interacted with full-length recombinant PAK4, 
the Δkinase domain, and, more specifically, the GTPase-bind-
ing domain (GBD; Fig. 2 D). We next performed the reverse set 
of experiments to determine which domain of RhoU (Fig. 2 E) 
bound to PAK4. We observed binding between PAK4 and both 
the ΔN- and ΔC-terminal mutants of RhoU, so we can therefore 
deduce that the region between these two termini, containing 
the effector and GTPase domains, most likely contributes to the 
interaction (Fig. 2 E).
Both Cdc42 and RhoU can interact with the GBD of 
PAK4, but we found that PAK4 (H19, 22L) can still bind to 
RhoU (Fig.  2  F) and indeed rescue the adhesion phenotype 
(Fig. 2 B). This result supports the notion that the critical res-
idues necessary for binding within the PAK4 GBD differs de-
pending on the GTPase species engaged. It is well established 
that RhoU can bind to and activate PAK1 (Tao et al., 2001). 
In cells coexpressing similar amounts of GFP-PAK1 and HA-
PAK4, we found that RhoU could still bind to either PAK1 or 
PAK4 to a similar level in the presence of the other (Fig. S2 
C); although there was a suggestion of a preference for PAK4, 
it was not statistically significant. Because neither PAK1 nor 
PAK4 could completely out-compete one another for binding to 
RhoU, we reasoned that the residues important within the RhoU 
effector domain crucial for interaction with PAK1 might differ 
from those of PAK4. PAK1 cannot bind to the RhoU 3M mutant 
(Ory et al., 2007), but we found that PAK4 was able to bind to 
it (Fig. S2, D and E). Thus, differential binding between the 
RhoU and PAK family proteins could account for the diverse 
biological functions of RhoU.
The interaction between RhoU and PAK4 is 
kinase independent
Because RhoU is closely related to Cdc42, we speculated that 
RhoU might regulate PAK4 activity during adhesion dynamics, 
especially given that Cdc42 binding is not required (Fig. 2 B). 
Autophosphorylation of PAK4 at S474 is thought to be a marker 
of kinase activity (Wells et al., 2010), but unlike that of group 
I PAKs, this autophosphorylation is not believed to entirely be 
a result of Rho GTPase binding (Baskaran et al., 2012; Ha et 
al., 2012). We found that phospho-PAK4 (S474) levels were 
unchanged in the presence of overexpressed RhoU (Fig. 3 A). 
Furthermore, RhoU was not identified as a substrate of PAK4 
(Fig. 3 B) and moreover, autophosphorylation of PAK4 and his-
tone H1 substrate phosphorylation were not enhanced by the 
presence of RhoU (compare Fig. S2 F with Fig. 3 B). There-
fore, it is likely that any functional outcome of the interaction 
between RhoU and PAK4 would be via a kinase-independent 
mechanism. RhoU is an atypical GTPase whose activity is more 
likely to be regulated by expression level or posttranslational 
modifications (Tao et al., 2001; Saras et al., 2004; Shutes et al., 
2004). Given that RhoU does not activate PAK4 and RhoU was 
not a PAK4 substrate, we considered whether PAK4 might reg-
ulate RhoU expression. Interestingly, we found that depletion of 
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Figure 1. Reduced PAK4 expression leads to an increase in MDA-MB-231 cell adhesion. (A, left) Immunohistochemical staining of human breast cancer 
tissues. Samples stained for PAK4 (brown) using an in-house PAK4-specific antibody and counterstained hematoxylin (blue) to reveal cellular structure. Bar, 
50 µm. (Right) Observed frequencies for modified H scores of PAK4 staining in human breast cancer tissue microarray. Modified H scores were generated 
by multiplying intensity (scored between 0 and 300) and percentage of cytoplasmic staining. χ2 p-values calculated for H scores associated with cancer 
grade. (B) WT, control, and PAK4 (Oligo1 and Oligo3) shRNA-expressing stable MDA-MB-231 cell lysates blotted with an in-house PAK4 antibody. GAP 
DH was used as a loading control. Control and PAK4 (Oligo1) shRNA-expressing MDA-MB-231 cell lysates also blotted for PAK4/6, phospho-PAK4/6, and 
PAK1. (C, top) F-actin staining of control and PAK4 shRNA-expressing MDA-MB-231 cells plated onto 10 µg/ml fibronectin and fixed after 60 min. Bar, 100 
µm. (Bottom) Adhesion assay of WT, control, and PAK4 shRNA-expressing MDA-MB-231 cells plated onto 10 µg/ml fibronectin for 60 min. Relative number 
 o
n
 M
ay 6, 2016
jcb.rupress.org
D
ow
nloaded from
 
Published November 23, 2015
JCB • Volume 211 • NumBer 4 • 2015866
PAK4 from MDA-MB-231 cells correlated with a loss of RhoU 
expression (Fig.  3  C), which could be replicated in MCF-7 
cells (Fig. S1 G). Conversely, when we overexpressed PAK4 
in MDA-MB-231 cells, an increase in endogenous RhoU pro-
tein expression was observed (Fig. S2 G). However, the mRNA 
expression of RhoU was not significantly unaltered in PAK4 
knockdown cells when compared with control cells, suggesting 
that PAK4 regulation of RhoU expression levels occurs post-
transcriptionally (Fig. 3 D), possibly via ubiquitination.
RhoU is ubiquitinated
Recently, it has been recognized that small GTPases, such as 
RhoA and Rac1, can be ubiquitinated as an alternative pathway 
to terminate signaling (Nethe and Hordijk, 2010). However, 
ubiquitination of RhoU had not been previously reported. We 
now find that RhoU can form RhoU–ubiquitin (Ub) conjugates 
(Fig. 3 E; HA-RhoU(Ub)n, visualized as multiple HA-positive 
bands that increase in size as RhoU–Ub levels are increased, 
rendering a gel smear; Rolli-Derkinderen et al., 2005; Visvikis et 
al., 2008). This shift in molecular weight is entirely consistent with 
increased ubiquitination (Rolli-Derkinderen et al., 2005; Visvi-
kis et al., 2008). The linkage specificity of ubiquitination can 
determine the stability of the target protein, where K48-linked 
ubiquitination targets substrates for proteasomal degradation, 
whereas K63-linked ubiquitination serves as a regulatory signal 
(Weissman, 2001). We next sought to confirm RhoU ubiquiti-
nation topologies. We used HA-tagged wild-type (WT) Ub and 
K48R and K63R Ub mutants, in which single lysine to arginine 
mutations at positions 48 and 63 are expected to disrupt Ub 
chain assembly. The mutation of K48 in Ub abolished RhoU 
ubiquitination, whereas the K63 mutation only moderately de-
creased the formation of RhoU–Ub conjugates (Fig. 3 E). This 
preferential K48-linked ubiquitination of RhoU is in line with a 
phenotype of RhoU degradation. Having confirmed that RhoU 
is targeted for ubiquitination, we next sought to identify the 
specific sites for Ub addition. Recent large-scale ubiquitome 
studies exploiting a combination of diglycine antibodies, pro-
teomics, and mass spectrometry have identified numerous in 
vivo ubiquitination sites (Kessler, 2013). Interestingly, one such 
study suggested that mouse RhoU has two putative ubiquitina-
tion sites, equivalent to K177 and K248 in human RhoU (Wag-
ner et al., 2012). Initially, we performed individual substitutions 
of the eight lysines present in the C-terminal sequence of RhoU 
to arginine and analyzed the mutated proteins using the Ub co-
immunoprecipitation assay. Of the eight lysines tested, only the 
RhoU K248R point mutant notably decreased the ubiquitination 
of RhoU (not depicted and Fig. 3 F), consistent with the previ-
ous predictions (Wagner et al., 2012). However, we observed 
that the RhoU ubiquitination signal was not completely lost in 
the RhoU K248R mutant. Thus, we reasoned the second pre-
dicted site (Wagner et al., 2012) on RhoU might also be ubiq-
uitinated. Indeed, it is common for proteins to have more than 
one ubiquitinated lysine (Rodriguez et al., 2000). Consequently, 
we produced a K to R point mutant of RhoU at position 177 as 
well as a double point mutant at positions 177 and 248. The sin-
gle RhoU K177R point mutant similarly reduced the ubiquiti-
nation of RhoU, and the double mutant RhoU K177, 248R also 
strongly impaired RhoU–Ub conjugate formation (Fig. 3 F). As 
a result, we propose that the major sites of ubiquitination in 
RhoU are lysines 177 and 248.
E3 Ub ligase Rab40A targets RhoU for 
ubiquitination
Ubiquitination of a protein is catalyzed by three enzymatic 
steps driven by a trio of enzymes, E1, E2, and E3, which in turn 
activate and deliver the Ub molecules to the targeted substrate. 
The last step of this process, whereby Ub is covalently attached 
to lysine residues within the target protein, is performed by 
an E3 Ub ligase (Nethe and Hordijk, 2010). We have used a 
high-throughput protein-binding microarray approach to screen 
a CDI HuProt microarray comprising of nearly 20,000 human 
full-length proteins for binding to RhoU, with specific emphasis 
on E3 ligases. Under rigorous and conservative criteria described 
in the supplementals, 121 proteins were identified as RhoU-in-
teracting proteins (Table S1), showing statistical significance 
(P < 0.05) and a positive ML value indicative of an increase 
in signal after RhoU treatment compared with control buffer 
alone. From this screen, we identified Rab40A, a Rab GTPase, 
as a binding partner for RhoU (Fig. 4 A). Human Rab40A is 
believed to be the substrate recognition/binding component of 
an SCF-like ECS (Elongin–Cullin–SOCS box protein) E3 Ub 
ligase complex by virtue of its homology to that of the Xenopus-
protein, which interacts with ElonginB/C and Cullin 5 to form a 
Ub ligase (Lee et al., 2007). GST pull-down analyses validated 
Rab40A as a RhoU-interacting protein and demonstrated that 
Cullin 5 can also form a complex with RhoU (Fig. 4 B).
To test whether Rab40A, via its Ub ligase activity, could 
indeed modulate RhoU stability, we overexpressed Rab40A and 
observed the level of endogenous RhoU. Rab40A overexpres-
sion consistently resulted in reduced RhoU levels, and, more-
over, coexpression of Rab40A and Cullin 5 further decreased 
RhoU protein (Fig.  4 C). In addition, an inactivated Cullin 5 
mutant (Cul5 K799R; Teckchandani et al., 2014) was unable to 
modulate RhoU levels (Fig. 4 C). Consistent with the involve-
ment of Rab40A and Cullin 5 in the down-regulation of RhoU, 
overexpression of the E3 Ub ligase complex promoted the ubiq-
uitination of RhoU (Fig. 4 D). These data support a role for the 
recruitment of RhoU by Rab40A to an ECS complex whereby 
it becomes ubiquitinated.
PAK4 protects RhoU from ubiquitination
Having confirmed that RhoU can be ubiquitinated and that 
ubiquitination can be delivered via a Rab40A complex, we 
reasoned that reducing Rab40A expression in PAK4-depleted 
cells would promote RhoU reexpression. Interestingly, though 
we did find that RhoU levels recovered (Fig. 4 E), we could not 
recover them to control levels. Thus, RhoU might be targeted 
by more than one E3 Ub ligase. Sharpin (SHA NK-associated 
RH domain–interacting protein), part of an E3 ligase complex, 
has been linked to adhesion dynamics (Rantala et al., 2011) and 
of adhered cells is absorbance at 560 nm. **, P < 0.01. (D) Paxillin labeling of MDA-MB-231 cells stably expressing control or PAK4 shRNA. Arrows high-
light the area in magnified insets. Bar, 20 µm. The mean number of focal adhesions per cell and the mean length of focal adhesions for all cell populations 
were measured using ImageJ software. n > 60 cells per condition over three independent experiments. *, P < 0.05; **, P < 0.01. (E) WT, control, and 
PAK4 knockdown MDA-MB-231 cells plated onto 10 µg/ml fibronectin were filmed for 18 h with time-lapse video microscopy. n, 60 individual cells per 
condition tracked over three separate experiments. The mean migration speed ± SEM were calculated for each condition. ***, P < 0.001. Ctrl, control.
 o
n
 M
ay 6, 2016
jcb.rupress.org
D
ow
nloaded from
 
Published November 23, 2015
A PAK4–rhou complex regulates adhesion • Dart et al. 867
Figure 2. PAK4 interacts with RhoU. (A) Schematic of PAK4 domain structure with N-terminal GBD and a C-terminal kinase domain. (B, left) Adhesion 
assay of Oligo1 PAK4-depleted MDA-MB-231 cells expressing shRNA-resistant mRFP-PAK4 derivatives plated onto 10 µg/ml fibronectin for 60 min. Rel-
ative number of adhered cells is absorbance at 560 nm. Error bars represent mean ± SEM. **, P < 0.01. (Right) F-actin staining of same cell conditions 
plated onto 10 µg/ml fibronectin and fixed after 60 min. Bar, 100 µm. (C) Anti–in-house PAK4 antibody coimmunoprecipitation of Cdc42 and RhoU from 
HEK-293 cells expressing HA-PAK4 and GFP-Cdc42 or GFP-RhoU. The control immunoprecipitation was rabbit anti-VSV-G antibody. (D) Purified GST, 
GST-PAK4, GST-PAK4 GBD, GST-PAK4 ΔGBD, GST-PAK4 kinase domain, and GST-PAK4 Δkinase domain beads were used to pull down GFP-RhoU from 
MDA-MB-231 cell lysates. Samples were analyzed by anti-GFP immunoblotting and Coomassie staining. Representative of three separate experiments. (E) 
Schematic of RhoU domain structure comprising of N-terminal proline-rich regions, a GTPase domain, and a C-terminal CAAX box motif. GST-PAK4 beads 
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was highlighted in our screen on the periphery of significance 
(Fig. 4 A). We find that Sharpin overexpression is also able to 
decrease endogenous RhoU levels (Fig. S2 H), suggesting that 
regulation of RhoU protein levels via ubiquitination is likely to 
be a complex spatial–temporal process.
The recovery of RhoU expression in cells codepleted of 
Rab40A and PAK4 strongly suggests that PAK4 plays an ac-
tive part in protecting RhoU from degradation. Thus, we next 
tested whether PAK4 could directly protect RhoU from ubiq-
uitination. We found that the prominence of RhoU–Ub conju-
gates was dramatically decreased in the presence of GFP-PAK4 
(loss of multiple HA-positive bands; Fig.  4, F and G). This 
result provides clear evidence that PAK4 protects RhoU from 
Ub-mediated protein degradation. The N-terminal extension of 
RhoU is thought to display an autoinhibitory function via bind-
ing to the GTPase domain  of RhoU (Shutes et al., 2004). We 
found that the N-terminal deletion mutant of RhoU (Fig. 4 F), 
which still binds to PAK4 (Fig. 2 E), was heavily ubiquitinated, 
and importantly, this was also protected by coexpression of 
PAK4 (Fig. 4 F). In contrast, deletion of the C-terminal resi-
dues including K248 (Fig. 3 F) almost completely abolished the 
ubiquitination of RhoU (Fig. 4 F), and this was not impacted 
by PAK4 overexpression. Importantly, we observed that both 
the kinase-dead and the Cdc42 binding–deficient mutants of 
PAK4, but not PAK4ΔGBD, were as equally competent as 
full-length PAK4 in reducing the amount of RhoU–Ub conju-
gates (Fig. 4 G). In combination, these data demonstrate that 
the interaction between RhoU and PAK4 is both sufficient and 
crucial for protecting RhoU from ubiquitination, but does not 
require PAK4 kinase activity.
RhoU expression can rescue PAK4 
knockdown phenotypes
Our data point to an interaction between PAK4 and RhoU that is 
kinase independent but when disrupted (by reduction of PAK4 
expression) leads to a loss of RhoU expression via ubiquiti-
nation. Given that RhoU expression has also been linked with 
adhesion disassembly in other cell types (Chuang et al., 2007; 
Ory et al., 2007; Bhavsar et al., 2013), we speculated that the 
PAK4 knockdown adhesion phenotype could be rescued by 
exogenous expression to restore RhoU to at least control lev-
els. Strikingly, GFP-RhoU was able to rescue the phenotype 
of PAK4-depleted cells (Fig.  5  A). Furthermore, a PAK4 ki-
nase-dead mutant (K350, 351M)r also significantly reduced 
adhesion compared with PAK4 knockdown cells (Fig.  5  A). 
RhoU rescues the augmented adhesion of PAK4 knockdown 
cells through a change in focal adhesion dynamics in the same 
manner as PAK4r expression (Fig.  5  B). Equally, the RhoU 
effector loop mutants (including RhoU 3M) were also able to 
alter the adhesion properties of PAK4-depleted cells by signifi-
cantly decreasing both the number and length of focal adhe-
sions (Fig. S3, A and B), demonstrating that PAK1 is not likely 
to be required for RhoU-mediated disassembly of focal adhe-
sions. Importantly, expression of PAK4r, both the PAK4 mu-
tants PAK4 (H19, 22L)r and PAK4 (K350, 351M)r, and RhoU 
was able to rescue the mean speed of cell motility in PAK4 
knockdown cells (MDA-MB-231 [Fig. 5 C] and MCF-7 [Fig. 
S1 F]), overall emphasizing a kinase-independent function for 
PAK4 in adhesion and migration upstream of RhoU and not 
requiring Cdc42 interaction.
Our data indicate a role for a PAK4–RhoU complex in 
focal adhesion disassembly. However, in some T cell lines, 
RhoU expression promotes adhesion (Bhavsar et al., 2013). 
Thus, we sought to define the precise involvement of RhoU in 
the regulation of focal adhesion disassembly in MDA-MB-231 
cells. Loss of RhoU expression significantly increased the cel-
lular adhesion, which could be rescued by the overexpression 
of RhoUr, a protein resistant to RNAi (Fig. 6, A and B). More-
over, we found significant differences in the number of focal 
adhesions (Fig. 6 C). This phenocopy of PAK4 knockdown has 
also been observed with knockdown of RhoU in both HeLa and 
NIH 3T3 cells (Chuang et al., 2007; Ory et al., 2007). Further-
more, mean cell migration speed was significantly decreased in 
RhoU shRNA-expressing cells (MDA-MB-231 [Fig. 6 D] and 
MCF-7 [Fig. S1 F]). Because of technical limitations of avail-
able antibodies, we were unable to localize endogenous RhoU, 
and GFP-RhoU overexpression routinely led to cell rounding, 
a consequence of enhanced adhesion disassembly that we have 
previously noted (Wells et al., 2002). However, on the rare oc-
casion where we could image GFP-RhoU, we were able to see 
localization in adhesions (Fig. S3 C). Thus, in MDA-MB-231 
cells, RhoU is more closely associated with adhesion disas-
sembly than formation and appears to function downstream of 
PAK4 in mediating adhesion disassembly.
RhoU promotes paxillin S272 
phosphorylation
Our previous work and others had demonstrated that PAK4-
driven phosphorylation of paxillin S272 is an essential step in 
cell adhesion turnover (Nayal et al., 2006; Wells et al., 2010). 
Indeed, we again find that PAK4-depleted MDA-MB-231 
cells exhibit reduced levels of paxillin S272 phosphorylation 
(Fig. 7 A), whereas reduction of PAK1 levels in MDA-MB-231 
cells by siRNA did not concomitantly decrease paxillin S272 
levels (Fig. S3 D). In our earlier study, we had not tested the ki-
nase dependence of the adhesion phenotype we observed (Wells 
et al., 2010). Unexpectedly, we now find that we can rescue the 
adhesion phenotype with exogenous expression of kinase-inac-
tive PAK4 or exogenous expression of RhoU (Fig. 5 A). This 
places RhoU firmly downstream of PAK4, and we hypothesized 
that perhaps it was in fact RhoU that drives paxillin S272 phos-
phorylation in a PAK4-dependent manner. Interestingly, exog-
enous RhoU overexpression in a PAK4-depleted background 
increases the level of paxillin S272 to an amount comparable 
to that of control cells (Fig. 7 A), and consistent with this re-
sult, we find RhoU in a complex with paxillin (Fig. 7 B). This 
finding argues for an additional kinase in the PAK4–RhoU 
complex mediating paxillin S272 phosphorylation. In support 
of this hypothesis, we noted that incubation with the serine/
threonine and tyrosine kinase inhibitor staurosporine dramati-
cally reduced the level of paxillin S272 in PAK4-depleted cells 
overexpressing RhoU (Fig.  7  C), thus suggesting the PAK4–
RhoU complex does indeed act as a scaffold to support paxil-
lin S272 phosphorylation.
were used to pull down HA-RhoU, HA-ΔNRhoU, HA-RhoUΔC, and HA-ΔNRhoUΔC. Samples were analyzed by anti-HA immunoblotting and Coomassie 
staining. Representative of three independent experiments. (F) GST or GST-PAK4 (H19, 22L) beads were used to pull down GFP-Cdc42V12 or GFP-RhoU 
from HEK-293 cell lysates. Blot is representative of three separate experiments. Ctrl, control.
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Figure 3. RhoU undergoes K48-linked ubiquitination. (A) Anti-PAK4 antibody was used to precipitate phospho-PAK4 (S474) from GFP or GFP-RhoU–trans-
fected MDA-MB-231 cell lysates. (B) An in vitro kinase assay was performed using 1 µg purified GST-PAK4 and 5 µg GST-RhoU. (Left) Coomassie staining 
demonstrates purified protein input. (Right) Phosphorylation was detected by autoradiography. The asterisk denotes a nonspecific band always observed in 
PAK4 kinase assays. (C) Lysates were made from control- and PAK4 shRNA-expressing MDA-MB-231 cells and analyzed by immunoblotting with anti-PAK4 
and RhoU antibodies. GAPDH was used as a loading control. Autoradiographs were quantified using ImageJ software, and the relative intensity of the 
PAK4 and RhoU signal was normalized to the loading control. The results shown are the means ± SEM of at least three independent experiments. ***, P 
< 0.001. (D) mRNA expression of RhoU and β-actin in control and PAK4 knockdown MDA-MB-231 cells as determined by RT-PCR. The relative intensity of 
the RhoU signal was normalized to the levels of β-actin. The results shown are the means ± SEM of three independent experiments. ns, not significant. (E) 
Anti-HA antibody coimmunoprecipitation of HA-Ub species and myc-RhoU from HEK-293 cells expressing HA-RhoU and either HA-Ub WT, HA-Ub K48R, 
or HA-Ub K63R. (F) Anti-Myc antibody coimmunoprecipitation of myc-Ub and HA-RhoU from HEK-293 cells expressing myc-Ub, HA-RhoU point mutants 
(expression plasmids with a lysine to arginine substitution at positions 177, 248, or both 177 and 248 as indicated), and GFP-PAK4. Ctrl, control.
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Figure 4. RhoU interacts with the E3 Ub ligase component Rab40A and is protected from ubiquitination by PAK4. (A) Protein microarray of RhoU–E3 
ligase interactions. Column headers are as follows: ID, GenBank accession number; AvgML, duplicate-summarized, loess-normalized, log2-transformed 
fluorescence intensity values obtained from the experimental array, minus those obtained from the negative control array; SD, standard deviation of the 
difference. P-value was calculated using a paired two-tailed t test for significance. P < 0.05 was considered to be statistically significant. (B) GST-RhoU pull-
down of GFP-Rab40A and T7–Cullin 5 (Cul5). Samples were analyzed by anti-GFP and T7 immunoblotting and Coomassie staining. Representative of three 
independent experiments. (C) Lysates were made from HEK-293 cells expressing GFP-Rab40A and/or T7–Cullin 5 (Cul5) or T7–Cullin 5 K799R (Cul5 KR) 
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PAK4 and RhoU expression is correlated 
across breast cancer cell lines
Collectively, our data point to an important regulatory rela-
tionship between PAK4 and the level of RhoU expression 
whereby RhoU is targeted for ubiquitination unless interact-
ing with PAK4. This relationship drives adhesion turnover and 
promotes cell migration. Together with our tissue microarray 
observations (Fig. 1 A), these data point to a role for PAK4 in 
promoting breast cancer progression. In line with this critical 
function of PAK4 in regulating the protein stability of RhoU, 
we observed a positive correlation (R2 = 0.712) between PAK4 
and RhoU protein levels in a panel of breast cancer cell lines 
(Fig. 7, D and E). Furthermore, both RhoU and PAK4 expres-
sion are elevated in metastatic MDA-MB-231 cells compared 
with a nontumorigenic (MCF-10A) control (Fig. 7 F), thus pro-
viding further evidence that an important physiological func-
tion of PAK4 is to stabilize cellular levels of RhoU to allow 
efficient cell migration.
Discussion
We found here that there is an unexpected kinase-indepen-
dent role for PAK4 during cell substratum adhesion turnover. 
We also found that PAK4-mediated adhesion dynamics do not 
require kinase activity or interaction with Cdc42. Rather, we 
have identified a novel kinase-independent function for PAK4 
in positively regulating the protein levels of RhoU. We have 
discovered that RhoU is preferentially K48 ubiquitinated and 
that this ubiquitination occurs on residues K177 and K248 of 
RhoU. Furthermore, we demonstrate that a Rab40A–Cullin 
5 complex targets RhoU for ubiquitination in PAK4-depleted 
cells. We now present a novel mechanistic pathway whereby 
PAK4 stabilization of RhoU directly influences the level of 
paxillin S272 phosphorylation. Collectively, these studies place 
PAK4 and RhoU at the center of cell substratum adhesion dy-
namics during migration.
An analysis of 300 human breast cancer samples re-
vealed that PAK4 expression was significantly associated with 
a high tumor grade that often leads to a poorer prognosis, the 
first time this has been reported in breast cancer. This result 
is even more significant given our finding that some import-
ant functions of PAK4 are not dependent on kinase activity, but 
on levels of expression.
In mesenchymal-like MDA-MB-231 cells and 
colony-forming MCF-7 cells, we found that reduced PAK4 
expression led to an increase in cell adhesion. This pheno-
type was also reported by us for colony-forming DU145 cells, 
where we demonstrated that the increased number and size of 
peripheral adhesions is a direct consequence of reduced ad-
hesion disassembly (Wells et al., 2010). In contrast, we did 
not find an adhesion phenotype in PAK4-depleted mesenchy-
mal-like PC3 cells (Ahmed et al., 2008; Whale et al., 2013). 
These divergent phenotypes likely reflect the predominance of 
one PAK4 signaling nexus over another in different cell types. 
Indeed, the work with PC3 cells had been performed in a back-
ground of hepatocyte growth factor stimulation (Ahmed et al., 
2008; Whale et al., 2013).
PAKs have been traditionally recognized to function 
downstream of the Rho family GTPases as effectors in a linear 
signaling cascade (Abo et al., 1998) where kinase activity is 
central to cellular outcome. However, we found no requirement 
for Cdc42 binding. Unexpectedly, we identified an interaction 
between RhoU and PAK4 that does not follow this effector 
convention. Although RhoU shares considerable sequence and 
functional similarity with the classical Rho GTPase Cdc42, it 
also has atypical characteristics that differentiate it. As an un-
conventional Rho GTPase, RhoU is believed to be constitutively 
active (Saras et al., 2004; Shutes et al., 2004), making its regula-
tion different from that of the guanine nucleotide exchange fac-
tor (GEF)–mediated mechanism of Cdc42 (Shutes et al., 2004). 
We reveal that RhoU, similar to other Rho GTPases (Nethe and 
Hordijk, 2010), is ubiquitinated, thus providing a novel mech-
anism through which RhoU signaling output can be controlled. 
In addition, we show that RhoU is primarily modified by K48-
linked polyubiquitin chains, likely acting as a proteolytic signal 
to target RhoU for proteasome-mediated degradation. However, 
we cannot rule out K63-linked ubiquitination; this form of post-
translational modification is thought to regulate the subcellular 
localization of the target protein (Wang et al., 2012), and K63 
linkage could influence RhoU accumulation into endosomes as 
a means of limiting RhoU-driven signaling.
By screening a human proteome microarray, we were able 
to identify an interaction between RhoU and Rab40A, a small 
GTP-binding protein. Rab40A contains a substrate recognition 
motif known as a SOCS (suppressor of cytokine signaling) box. 
This motif in other proteins has been shown to provide sub-
strate specificity, and through direct binding to the substrate, it 
bridges the target protein to Elongin and Cullin proteins, which 
together constitute a multisubunit ECS complex with Ub ligase 
activity (Kile et al., 2002). In Xenopus, XRab40 (the homologue 
of human Rab40A) is one component of an E3 Ub ligase, along 
with ElonginB/C and Cullin 5. As such, the XRab40-containing 
ECS complex ubiquitinates the GTPase Rap2 that in turn reg-
ulates its localization and influence over downstream effectors 
in the noncanonical Wnt signaling pathway (Lee et al., 2007). 
It has already been established that Wnt signaling can regulate 
expression levels of RhoU (Schiavone et al., 2009; Dickover 
et al., 2014), and notably, we also identified Wnt6 (Kirikoshi 
et al., 2001) as a putative interacting partner of RhoU (Table 
S1). Hence, we predicted that RhoU could be a substrate for 
ubiquitination by a Rab40A-containing complex in humans, 
and in validation, we showed that overexpression of Rab40A 
can reduce endogenous levels of RhoU through its enhanced 
and immunoblotted with anti-GFP and RhoU antibodies. GAP DH was used as a loading control. UT, untransfected. Autoradiographs were quantified using 
ImageJ software, and the relative intensity of the RhoU signal was normalized to the loading control. The results shown are the means ± SEM of at least 
three independent experiments. ***, P < 0.001. ns, not significant. (D) Coimmunoprecipitation of myc-Ub and HA-RhoU from HEK-293 cells expressing 
myc-Ub, HA-RhoU, and either GFP-Rab40A, T7–Cullin 5 (Cul5), or GFP-Rab40A and T7–Cullin 5. (E) Lysates from MDA-MB-231 cells where PAK4 had 
been silenced or PAK4 had been silenced in combination with Rab40A after 48 h and immunoblotted with anti-PAK4, RhoU, and Rab40A antibodies. GAP 
DH was used as a loading control. Autoradiographs were quantified using ImageJ software, and the relative intensity of the RhoU signal was normalized 
to the loading control. The results shown are the means ± SEM of at least three independent experiments. *, P < 0.05; ***, P < 0.001. (F) Anti-Myc 
antibody coimmunoprecipitation of myc-Ub and HA-RhoU from HEK-293 cells expressing myc-Ub, HA-RhoU domain mutants, and GFP-PAK4. (G) Anti-Myc 
antibody coimmunoprecipitation of myc-Ub and HA-RhoU from HEK-293 cells expressing myc-Ub, HA-RhoU, and GFP-tagged PAK4 mutants. Ctrl, control.
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Figure 5. RhoU functions downstream of PAK4 in MDA-MB-231 cell adhesion and migration. (A, left) Adhesion assay of Oligo1 PAK4-depleted 
MDA-MB-231 cells expressing GFP-RhoU or shRNA-resistant mRFP-PAK4 (K350, 351M) plated onto 10 µg/ml fibronectin for 60 min. The relative number of 
adhered cells is absorbance at 560 nm. **, P < 0.01; ***, P < 0.001. (Right) F-actin staining of these same cell conditions plated onto 10 µg/ml fibronec-
tin and fixed after 60 min. Bar, 100 µm. (B) Paxillin labeling of control and Oligo1 PAK4-depleted MDA-MB-231 cells expressing either shRNA-resistant 
mRFP-PAK4 or mRFP-RhoU. Bar, 20 µm. The mean number of focal adhesions and the mean length of focal adhesions for Oligo1 PAK4 shRNA-expressing 
MDA-MB-231 cells also expressing mRFP-RhoU or shRNA-resistant mRFP-PAK4 were measured using ImageJ software. n > 60 cells per condition over three 
independent experiments. *, P < 0.05. (C) Control and Oligo1 PAK4-depleted MDA-MB-231 cells expressing shRNA-resistant mRFP-PAK4, -PAK4 (H19, 
22L), -PAK4 (K350, 351M), or mRFP-RhoU plated onto 10 µg/ml fibronectin were filmed for 18 h with time-lapse video microscopy. Mean migration speed 
± SEM was calculated by tracking 60 individual cells per population (n) over three separate experiments. ***, P < 0.001. Image stills from the videos 
depicting typical cell morphologies. Bar, 20 µm. Ctrl, control.
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ubiquitination. Interestingly, we were also able to demonstrate 
that overexpressed Cullin 5 leads to a decreased level of RhoU, 
and together with Rab40A, overexpression resulted in an addi-
tive effect on RhoU degradation and ubiquitination. Our data, 
although identifying Rab40A as a key E3 ligase component for 
RhoU ubiquitination, also highlighted that other potential E3 
ligases (such as Sharpin) may either compensate for the func-
tion of Rab40A or be acting autonomously on RhoU, a find-
ing that would seemingly fit with RhoU being ubiquitinated on 
more than one site and undergoing two types of lysine linkage 
additions. It will be important in the future to investigate the 
full impact of Sharpin function on RhoU. It should be noted 
that because of the stringent binding conditions used to perform 
the microarray, only tight regulatory interactions were revealed, 
likely explaining why PAK4 and PAK1 were not identified as 
highly significant hits.
Our data clearly demonstrate that PAK4 is able to pro-
tect RhoU from ubiquitination, independent of kinase function. 
PAK4 protection is delivered through the GBD of PAK4, a 
novel function for this domain, and to our knowledge, this is the 
first example of positive modulation of protein levels by PAK4. 
Therefore, we present PAK4 as a novel regulator of RhoU func-
tion rather than the accepted term “effector.” Indeed, we have 
found that PAK4 and RhoU expression is correlated in a panel 
of breast cancer cell lines, suggesting that the relationship be-
tween PAK4 and RhoU expression is not confined to the cell 
types studied here. In agreement with the model that up-regula-
tion of PAK4 and RhoU can promote migratory phenotypes in 
Figure 6. RhoU controls MDA-MB-231 cell adhesion and motility. 
(A) WT MDA-MB-231 cells were transiently transfected with control 
or RhoU (1 and 2) shRNA, and protein levels were determined after 
48 h by immunoblotting. (B) Adhesion assay of WT, control, and 
RhoU shRNA-expressing MDA-MB-231 cells plated onto 10 µg/
ml fibronectin for 60 min. The relative number of adhered cells is 
absorbance at 560 nm. Error bars represent mean ± SEM. **, P < 
0.01. (C) Paxillin labeling of MDA-MB-231 cells transiently express-
ing control or RhoU shRNA. The arrows highlight magnified insets. 
Bar, 20 µm. The mean number of focal adhesions per cell for all 
cell populations were measured using ImageJ software. n > 60 cells 
per condition over three independent experiments. **, P < 0.01. 
(D) Control and RhoU shRNA-expressing MDA-MB-231 cells plated 
onto 10 µg/ml fibronectin were filmed for 18  h with time-lapse 
video microscopy. Mean migration speed ± SEM was calculated by 
tracking 60 individual cells per population (n) over three separate 
experiments. *, P < 0.05; **, P < 0.01. Image stills from the videos 
depict typical cell morphologies. Bar, 20 µm. Ctrl, control.
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breast carcinoma are the observations that Rab40A (Oncomine 
Research Edition; Neve and Bild datasets accessed May 2015) 
and Cullin 5 (Fay et al., 2003) genes are frequently underex-
pressed in breast cancer cell lines and tissues.
Interestingly, Rac1 Ub conjugates localize preferen-
tially to endosomal structures, whereas a mutant of Rac1 
that cannot be ubiquitinated displays increased accumula-
tion at the plasma membrane (Nethe et al., 2010). In agree-
ment with this, we have noted an increase in vesicular RhoU 
upon expression of the ΔN mutant that is heavily ubiquiti-
nated, contrasting with the expression of the ΔC mutant 
that is not present in vesicles (unpublished data). Consistent 
with the notion that ubiquitination of RhoU could drive its 
subsequent internalization into EEA1-positive endosomes is 
the functioning of Rab GTPases in vesicle trafficking and, 
more specifically, of Rab40 in recycling endosomes (Jean 
and Kiger, 2012). Moreover, this type of signaling pathway 
has parallels with that of H-Ras, which is ubiquitinated by 
Rab5 GEF Rabex-5, resulting in its sequestration into early 
endosomes and most likely preventing its interaction with 
downstream effectors (de la Vega et al., 2011). It is also 
an attractive possibility to speculate that the interaction be-
tween RhoU and PAK4, besides providing protection from 
ubiquitination, could offer a reciprocal advantage in local-
ization. Interactions between Cdc42 and PAK4 have been 
shown to target the kinase to specific cellular compartments, 
such as the Golgi apparatus and cell–cell adherens junctions 
(Abo et al., 1998; Wallace et al., 2010). Therefore, in a sim-
ilar manner, it may be that RhoU could spatially restrict 
PAK4 at focal adhesions.
RhoU has been implicated in focal adhesion dynam-
ics previously, but its exact role has been controversial. 
RhoU accumulates in osteoclast podosomes as well as 
the focal adhesions of HeLa and NIH 3T3 cells (Chuang 
et al., 2007; Ory et al., 2007) and is linked to adhesion 
disassembly. In contrast, in T-ALL cell lines, RhoU pro-
motes adhesion (Bhavsar et al., 2013). However, we find 
that a loss of RhoU expression in MDA-MB-231 cells de-
Figure 7. RhoU can influence the serine phos-
phorylation of paxillin. (A) Blots showing the 
levels of paxillin (S272) in control and PAK4 
shRNA MDA-MB-231 cells overexpressing 
GFP-RhoU plated onto 10 µg/ml fibronectin. 
(B) GST-RhoU beads were used to pull down 
overexpressed GFP-PAK4 and GFP-paxillin 
from MDA-MB-231 cell lysates. Representa-
tive of three separate experiments. (C) Blots 
showing the levels of paxillin (S272) in PAK4 
shRNA MDA-MB-231 cells overexpressing 
GFP-RhoU in the absence (DMSO control) or 
presence of 20-nM staurosporine. All cells 
were plated onto 10 µg/ml fibronectin. (D) 
Immunoblot analysis of RhoU and PAK4 pro-
tein expression in breast tumorigenic cell lines. 
(E) Densitometry analyses of RhoU and PAK4 
levels relative to levels of the GAP DH load-
ing control in breast tumorigenic cell lines. 
Values are means ± SEM from at least three 
experiments. Squared correlation value be-
tween PAK4 and RhoU (R2) equals 0.712. (F) 
Immunoblot analysis of RhoU and PAK4 pro-
tein expression in a mammary epithelial cell 
line (MCF-10A) compared with breast cancer 
cells MCF-7 and MDA-MB-231. For D and 
F, labels are as follows: IDC, invasive ductal 
carcinoma; DC, ductal carcinoma; AC, ade-
nocarcinoma; F, fibrocystic disease, nontrans-
formed, immortal cell line. Invasive potential is 
defined as not invasive (−), invasive (+), and 
highly invasive (++; Tong et al., 1999; Neve 
et al., 2006). Ctrl, control.
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livers increased adhesion. Moreover, the depletion of RhoU 
drives the same phenotype as the loss of PAK4 in these 
cells, again suggesting that these two proteins coordinate to 
regulate adhesion turnover. 
We have previously reported that PAK4 can phosphory-
late paxillin at S272 in vitro and that S272 phosphorylation of 
paxillin is a driver of adhesion disassembly (Wells et al., 2010). 
Consistent with our earlier work, paxillin S272 phosphoryla-
tion was reduced upon depletion of PAK4 in MDA-MB-231 
cells. Furthermore, we found no evidence for PAK1 regulation 
of paxillin S272 phosphorylation. Recently, an alternative path-
way to focal adhesion disassembly was reported in endothelial 
cells that requires RhoJ and the GIT–PIX complex (Wilson et 
al., 2014) with the implication that PAK1 is required. However, 
PAK4 does not interact with RhoJ, a cycling Rho GTPase whose 
regulation is likely to be via GEF activity (Vignal et al., 2000). 
PAK1 protein levels are normal in our PAK4-depleted cells, 
and therefore PAK1 is unable to compensate for a loss of PAK4 
with respect to paxillin phosphorylation. Indeed, PAK1 does 
not phosphorylate paxillin at S272 in vitro (Dong et al., 2009), 
and in our hands, the depletion of PAK1 does not alter focal 
adhesion dynamics in breast cancer cells. We thus conclude that 
PAK4 is the predominant PAK species regulating paxillin-me-
diated focal adhesion turnover in breast cancer cells. Moreover, 
we now believe that although PAK4 can phosphorylate paxillin 
in vitro, in cellulo PAK4 delivers paxillin phosphorylation in a 
kinase-independent manner via stabilization of RhoU (Fig. 8).
This unexpected conclusion is derived from our data 
revealing that overexpression of RhoU could elevate the 
level of paxillin S272 phosphorylation in PAK4-depleted 
cells. Overexpression of RhoU could allow residual PAK4 
to be targeted to paxillin, but we have extremely low levels 
of PAK4 expression in our knockdown cells, and our data 
firmly argue for a kinase-independent pathway, given that ki-
nase-dead PAK4 can rescue the adhesion phenotype. Thus, it 
is more likely that we have identified an alternative signaling 
pathway to paxillin S272 phosphorylation. Indeed, we were 
able to show that RhoU exerts its actions through a stauros-
porine-sensitive mechanism. Staurosporine inhibits a range 
of kinases such as PKC, PKA, PKG, and myosin light chain 
kinase (Omura et al., 1995), and as such, we can only specu-
late on the precise nature of the protein kinase modulated by 
RhoU. Of these candidates, myosin light chain kinase is an 
attractive possibility given that RhoU depletion can decrease 
myosin regulatory light chain phosphorylation (Chuang et 
al., 2007). Another hypothesis is that RhoU, via PKA, could 
produce a positive reinforcing feedback loop by virtue of 
the capacity of PKA itself to phosphorylate PAK4 (Park et 
al., 2013). Thus, the relationship between PAK4, RhoU, and 
PKA warrants further study.
In conclusion, we present a new view on the role of 
PAK4 in cell adhesions where a major function of PAK4 
is to stabilize RhoU, which in turn leads to focal adhesion 
disassembly via phosphorylation of paxillin. We further 
propose that PAK4 expression is a component of breast 
cancer progression, thus supporting the notion that PAK4 
is an attractive candidate drug target. However, to date, all 
PAK4-specific inhibitors developed have been competitive 
ATP inhibitors (Murray et al., 2010; Zhang et al., 2012). In 
light of our findings, we suggest that efforts should also be 
made to develop allosteric inhibitors that could ultimately 
provide significant target selectivity.
Materials and methods
Antibodies and reagents
Unless indicated, primary antibodies were used at a dilution of 1:1,000 
for Western blotting. Anti-GAP DH was purchased from EMD Millipore 
and used at a dilution of 1:20,000. Rabbit anti-PAK1, rabbit anti–phos-
pho-PAK4 (S474)/PAK5 (S602)/PAK6 (S560), and rabbit anti-PAK4, 
which also recognizes PAK6 (Ahmed et al., 2008), were purchased 
from Cell Signaling Technology. Rabbit polyclonal PAK4-specific 
antibody (raised against PAK4 peptide sequence CRR AGPEK RPKSS 
REG) has been described elsewhere (Wells et al., 2010). Rabbit an-
ti-RhoU (Wrch1) and rabbit anti-Rab40A were obtained from Abcam 
and used at a dilution of 1:500. Mouse anti-GFP was obtained from 
Roche and mouse anti-T7 from EMD Millipore. Rabbit anti-HA (Y-11) 
and mouse c-Myc (9E10) were purchased from Santa Cruz Biotech-
nology, Inc. Mouse antipaxillin were obtained from BD, rabbit an-
ti-phosphopaxillin S273(272) from Invitrogen, and mouse antivinculin 
from Sigma-Aldrich. HRP-conjugated secondary antibodies were pur-
chased from Dako and diluted 1:2,000. Staurosporine was purchased 
from Cell Signaling Technology and dissolved in DMSO.
DNA constructs
Vectors encoding myc-Ub, GFP-Cdc42V12, and GFP-RhoU were 
gifts from R. Kopito (Stanford University, Stanford, CA), M. Parsons 
(King’s College London, London, England, UK), and P. Aspenstrom 
(Karolinska Institute, Stockholm, Sweden), respectively. Vectors en-
coding GFP-tagged RhoU effector point mutants (T81S, F83A, F86C, 
and 3M) were a gift from A. Blangy (Centre National de la Recherche 
Scientifique, Montpellier, France). HA-Ub, HA-Ub K48R, and HA-Ub 
Figure 8. PAK4 drives kinase-independent stabilization of RhoU to regu-
late cell adhesion and motility. Schematic illustrating how PAK4 and RhoU 
converge on paxillin phosphorylation at S272. PAK4 regulates the stability 
of RhoU through protection from ubiquitination by a Rab40A–Cullin 5 com-
plex and scaffolds paxillin, allowing RhoU to drive modulation of paxillin 
S272 phosphorylation. Ultimately, this signaling contributes to focal adhe-
sion disassembly and, consequently, efficient cell migration.
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K63R were all gifts from K.L. Lim (National Neuroscience Institute, 
Singapore). T7–Cullin 5 and T7–Cullin 5 (K799R) were gifts from 
J.A. Cooper (Fred Hutchinson Cancer Research Center, Seattle, WA), 
and GFP-Rab40A and GFP-Sharpin were gifts from J. Ramalho (Cen-
tro de Estudos de Doencas Cronicas, Lisbon, Portugal) and J. Ivaska 
(Turku Centre for Biotechnology, Turku, Finland), respectively. cDNA 
of PAK4, PAK4r (containing silent shRNA refractory mutations), GBD 
domain (amino acids 1–30), ΔGBD domain (amino acids 30–591), ki-
nase domain (encoding amino acids 323–591), Δkinase domain (amino 
acids 1–322), PAK4 (H19, 22L), PAK4 (H19, 22L)r, and PAK4 (K350, 
351M)r was previously cloned into pDONR207 using BP recombi-
nation (Gateway; Thermo Fisher Scientific) to generate entry vectors 
(Wells et al., 2010; Whale et al., 2013). PAK4 derivatives were then 
transferred into either mammalian mRFP or bacterial GST expression 
destination vectors using LR recombination (Gateway). PAK1, RhoU, 
ΔNRhoU (encoding amino acids 45–258), RhoUΔC (amino acids 
1–223), and ΔNRhoUΔC (amino acids 45–223) cDNA was cloned 
into pDONR207 using BP recombination to generate pENTR-RhoU, 
-ΔNRhoU, -RhoUΔC, and -ΔNRhoUΔC, respectively. The RhoU 
derivatives were then transferred into either mammalian 3xHA or 
bacterial GST and HIS expression vectors using LR recombination. 
Point mutations were introduced into pENTR-RhoU using primers 
designed with the mutagenic primer design program (QuikChange; 
Agilent Technologies). The mutagenesis kit was used according to 
manufacturer’s instructions to generate a pENTR-RhoUr (containing 
silent shRNA refractory mutations) and multiple pENTR-RhoU K-to-R 
mutants. Clones were screened by sequencing and aligned to the WT 
sequence to confirm mutagenesis. The sequence-verified mutant was 
then transferred into mammalian mRFP and EGFP expression desti-
nation vectors using linker region recombination. All constructs were 
verified by sequencing.
Cell culture and transfection
MDA-MB-231 breast adenocarcinoma cells and all other breast cancer 
cell lines were obtained from the European Tissue Culture Collection 
and grown in complete DMEM (Sigma-Aldrich) supplemented with 
10% FCS (Sigma-Aldrich) and 100 U/ml penicillin-streptomycin. 
MDA-MB-231 cells were transiently transfected using Lipofectamine 
2000 transfection reagent (Invitrogen) according to the manufacturer’s 
protocol. HEK-293 cells (European Tissue Culture Collection) were 
grown in complete DMEM, supplemented with 10% FCS and 100 
U/ml penicillin-streptomycin, and transfected by calcium-phosphate 
transfection according to the manufacturer’s protocol. For inhibitor ex-
periments, staurosporine was incubated with cells in a serum-starved 
medium at a final concentration of 20 nM for 3 h before lysis.
shRNA and siRNA transfection
To generate stable control and PAK4 knockdown MDA-MB-231 cell 
lines, cells were transfected with control or PAK4-specific pGIPz 
lentiviral bicistronic vectors using Lipofectamine 2000 according 
to the manufacturer’s protocol. Open Biosystems Oligo IDs were as 
follows: nonsilencing control RHS4346 (sequence 5′-ATC TCGCT 
TGGGC GAGAG TAAG-3′), Oligo1 V2LHS_197812 (sequence 5′-
CTG GACAA CTTCA TCAAGA-3′), and Oligo3 V3LHS_646396 (se-
quence 5′-CGA TCATG AATGT CCGAAG-3′). Stable cell lines were 
puromycin selected (700 ng/ml) before cell sorting to isolate TurboG-
FP-expressing cells (polyclonal cells) and maintained in a medium 
supplemented with 700 ng/ml puromycin. Knockdown of RhoU was 
achieved by transient transfection of pLKO.1 vectors containing RhoU 
shRNA inserts (RhoU1 sequence 5′-CGG ACAGG ATGAA TTTGA 
CAA-3′ and RhoU2 sequence 5′-CTA CATCG AGTGT TCAGC CTT-
3′), a gift from A. Ridley (King’s College London, London, England, 
UK), using Lipofectamine 2000. Transient knockdown of PAK4 in 
MCF-7 cells was achieved using human PAK4 siRNA oligonucleotide 
2 (S102660315; sequence 5′-CGA GAATG TGGTG GAGAT GTA-3′; 
QIA GEN) and oligonucleotide 5 (D-003615-05; sequence 5′-GGG 
TGAAG CTGTC AGACTT-3′; GE Healthcare). Transient knockdown 
of PAK1 and PAK2 in MDA-MB-231 cells was achieved using SMA 
RTpool ON-TAR GETplus human PAK1 siRNA (L-003521-00-0005; 
sequences 5′-GGA GAAAU UACGA AGCAUA-3′, 5′-UCA AAUAA 
CGGCC UAGACA-3′, 5′-ACC CAAAC AUUGU GAAUUA-3′, and 
5′-CAU CAAAU AUCAC UAAGUC-3′; GE Healthcare) and SMA 
RTpool ON-TAR GETplus human PAK2 siRNA (L-003597-00-0005; 
sequences 5′-GAA ACUGG CCAAA CCGUUA-3′, 5′-GAG CAGAG 
CAAAC GCAGUA-3′, 5′-ACA GUGGG CUCGA UUACUA-3′, and 5′-
GAA CUGAU CAUUA ACGAGA-3′; GE Healthcare). Transient knock-
down of Rab40A was attained by using individual human siGEN OME 
Rab40A siRNA oligonucleotides 1 and 2 (D-008924-01 and D-008924-
05; sequences 5′-GCA AACCG CUGGU CUUUCG-3′ and 5′-GGG 
UAUGG AUCGA UGGAUU-3′, respectively; GE Healthcare). Control 
RNA oligonucleotides were purchased from QIA GEN (1022076; se-
quence 5′-AAT TCTCC GAACG TGTCA CGT-3′). Control and PAK4-, 
PAK1-, PAK2-, and Rab40A-specific oligonucleotides were added to 
cells using a HiPerFect Transfection Reagent (QIA GEN) according to 
the manufacturer's instructions to a final concentration of 30 nM. Ef-
ficiency of knockdown was assessed by Western blotting after 48 h.
Immunofluorescence and image analysis
Cells were seeded onto human fibronectin (10 µg/ml; Sigma-Al-
drich)-coated coverslips. After transfection or incubation overnight, 
cells were fixed in 4% paraformaldehyde in PBS for 20 min at RT and 
subsequently permeabilized with 0.2% Triton X-100 in PBS for 5 min. 
For F-actin staining, cells were incubated with either TRI TC- or Alexa 
Fluor 488–conjugated phalloidin (Invitrogen) and diluted in PBS for 
1 h at RT. After this incubation, cells were washed three times in PBS. 
For detection of paxillin, primary antibodies were diluted in PBS with 
3% BSA (Thermo Fisher Scientific) and incubated for 2 h at RT. After 
labeling with the primary antibodies, cells were washed three times 
with PBS before incubation with either Alexa Fluor 568– or 488–con-
jugated secondary antibodies (Invitrogen) and phalloidin. Cells were 
then imaged using either a microscope (IX71; Olympus) with a 40× 
oil-immersion objective (UPlanFLN) with a numerical aperture of 
1.3 and Image-Pro Plus software (Media Cybernetics) or a confocal 
laser-scanning microscope (LSM510; Carl Zeiss) with a Plan Fluorite 
100× oil objective with a numerical aperture of 1.45 and the accom-
panying LSM510 software. Focal adhesion number and length were 
quantified using ImageJ software (National Institutes of Health).
Time-lapse microscopy
Cells were plated onto fibronectin-coated 6-well plates, to which 
25-mM Hepes was added. Immediately before filming, MCF-7 cells 
were treated with 100 ng/ml EGF to induce motility (Garcia et al., 
2006). Each plate was placed on the automated heated stage of an 
microscope (IX71) set at 37°C and imaged with a 10× objective lens 
(UPlanFLN) with a numerical aperture of 0.3. Images were collected 
using a charge-coupled device camera (Retiga-SRV; QImaging), taking 
a frame every 5 min for 18 h from each of the wells using Image-Pro 
Plus software. Subsequently, all of the acquired time-lapse sequences 
were displayed as a video, and cells were tracked for the whole of the 
time-lapse sequence using motion analysis software (Andor Technol-
ogy). This resulted in the generation of a sequence of position coordi-
nates relating to each cell in each frame. At least 60 cells were tracked 
over three separate films for each experimental condition. Mathemat-
ical analysis was then performed using Mathematica 6.0 notebooks 
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(Wolfram) developed in-house by G.  Dunn and G.E.  Jones (King’s 
College London, London, England, UK). Statistical significance 
was accepted for P ≤ 0.05.
Adhesion assay
Cells were seeded at 5 × 104 on 24-well plates that were precoated 
with 10 µg/ml fibronectin (Sigma-Aldrich). After 60 min at 37°C, the 
cells were washed twice with PBS, incubated in 500 µg/ml methylth-
iazoletetrazolium (Sigma-Aldrich), and diluted in complete DMEM 
for 3 h to detect viable cells that were still adhered to the substrate. 
The converted dye was then solubilized for 10 min using DMSO. Fi-
nally, the absorbance at 540 nm was measured using an alpha fusion 
plate reader (PerkinElmer).
Immunohistochemical staining
In brief, formalin-fixed, paraffin-embedded human breast cancer tissue 
samples were stained with an in-house PAK4-specific antibody (Wells 
et al., 2010) using the BondMax system (Leica).
RT-PCR
Total RNA was isolated from WT, control, and PAK4 knockdown 
MDA-MB-231 cells using the RNeasy kit (QIA GEN) according to the 
manufacturer’s protocol. Reverse transcription was performed with 
the High Capacity RNA-to-cDNA kit (Applied Biosystems) accord-
ing to the manufacturer’s instructions. The cDNA obtained from the 
reverse transcription reaction was then used in a PCR with REDTaq 
ReadyMix PCR Reaction Mix with MgCl2 (Sigma-Aldrich). RT-PCR 
products were resolved by electrophoresis in 1.5% ethidium bro-
mide–stained agarose gels.
Immunoprecipitation
Cells were lysed for 10 min in a lysis buffer (0.5% NP-40, 30-mM 
sodium pyrophosphate, 50-mM Tris-HCl, pH 7.6, 150-mM NaCl, 
0.1-mM EDTA, 50-mM NaF, 1-mM Na3VO4, 1-mM PMSF, 10 µg/
ml leupeptin, and 1 µg/ml aprotinin) and clarified by centrifugation at 
16,200  g for 10 min. Cell lysates were then incubated with primary 
rabbit anti-PAK4 antibody or an isotype control antibody (rabbit anti–
VSV-G; Bethyl Laboratories, Inc.) overnight at 4°C followed by 1-h 
incubation with protein A–Sepharose beads (GE Healthcare). The 
immune complexes were washed three times with a lysis buffer and 
resuspended in 2× SDS loading buffer. Proteins were resolved by SDS-
PAGE as previously described (Wells et al., 2002) and immunoblotted 
with the relevant antibodies.
GST-tagged protein purification and pull-down assays
GST proteins were purified from BL21-A1 cells (Invitrogen). In brief, 
bacterial cells were transformed with pDEST15-GST-PAK4, -GBD 
domain, -ΔGBD domain, -kinase domain, -Δkinase domain, -(H19, 
22L), or GST-RhoU expression vectors and cultured in a lysogeny 
broth supplemented with 100 µg/ml ampicillin until OD600 0.4–0.6. Re-
combinant protein synthesis was induced overnight at 20°C with 0.2% 
l-arabinose. Bacterial pellets were lysed in PBS containing complete 
mini-protease inhibitor tablet (Roche) followed by sonication and cen-
trifugation at 15,000 g for 10 min at 4°C to remove cell debris. The 
supernatant was then incubated with prewashed glutathione Sepharose 
4B beads (GE Healthcare) for 2 h at 4°C, and the GST fusion protein–
coupled beads were collected by centrifugation, washed three times, 
and stored in 50% glycerol, 20-mM Tris-HCl, pH 7.6, 100-mM NaCl, 
and 1-mM DTT. Transfected HEK-293 cells were lysed in 0.5% NP-
40, 30-mM sodium pyrophosphate, 50-mM Tris-HCl, pH 7.6, 150-mM 
NaCl, 0.1-mM EDTA, 50-mM NaF, 1-mM Na3VO4, 1-mM PMSF, 10 
µg/ml leupeptin, and 1 µg/ml aprotinin. Lysates were then precleared by 
incubation with glutathione Sepharose 4B beads for 1 h at 4°C. These 
precleared lysates were incubated with the GST fusion protein beads 
for 2 h at 4°C, collected by centrifugation, washed three times with a 
lysis buffer, and resuspended in a 2× SDS loading buffer.
Kinase assay
Bound GST-RhoU and -PAK4 proteins to be used in kinase assays were 
eluted from glutathione Sepharose beads and purified as follows. Beads 
were rotated for 30 min at 4°C in an elution buffer (100-mM Tris, pH 
8, 150-mM NaCl, 5-mM reduced l-glutathione [Sigma-Aldrich], and 
1-mM DTT) before being spun down at 500 g for 1 min. The eluate 
was then dialysed overnight at 4°C in a dialysis buffer (100-mM Tris, 
pH 8, and 150-mM NaCl) using dialysis tubing (Visking; VWR), after 
which purified GST proteins were incubated in a kinase buffer (50-mM 
Tris-HCl, pH 7.5, 10-mM MgCl2, and 1-mM DTT) containing 30-µM 
ATP and 3 µCi γ-[32P]ATP together with histone H1 (Roche) for 30 min 
at 30°C. The reaction was stopped by adding an SDS loading buffer.
HIS-tagged protein purification
HIS-RhoU was purified from BL21-A1 cells (Invitrogen). In brief, bac-
terial cells were transformed with the pDEST15-HIS-RhoU expression 
vector and cultured in an LB broth supplemented with 100 µg/ml ampi-
cillin until OD600 0.4–0.6. Recombinant protein synthesis was induced 
overnight at 20°C with 0.2% l-arabinose. Bacterial pellets were lysed 
in PBS containing complete mini-protease inhibitor tablets followed by 
sonication and centrifugation at 15,000 g for 10 min at 4°C to remove 
cell debris. The supernatant was then incubated with Ni2+ nitrilotria-
cetate agarose beads (QIA GEN) for 2  h at 4°C, and the HIS fusion 
protein–coupled beads were collected by centrifugation and washed ex-
tensively. For use in the subsequent Ub protein microarray, HIS-tagged 
RhoU was eluted from the agarose beads by incubation of the resin in 
250-mM imidazole, pH 7, for 10 min with rotation and then centrifuged 
at 500 g for 5 min. The elution step was repeated once more, and the 
purified protein fractions were pooled. Purified protein was then dial-
ysed overnight at 4°C in PBS using dialysis tubing (Visking).
Protein microarray
An E3 ligase identification service (LifeSensors) was used to identify 
the E3 ligase involved in the ubiquitination of RhoU. CDI-Labs HuProt 
V2.0 arrays with ∼20,000 human proteins were exposed to recombi-
nant HIS-tagged RhoU or a buffer alone. Arrays were blocked for 1 h 
at RT in PBS containing 0.05% Tween 20, 20-mM reduced glutathione, 
1-mM DTT, 5% BSA, and 25% glycerol. One array was treated with 
RhoU (100 nM) and a second, control array was treated with a buffer 
for 1 h at RT. Arrays were then washed three times in PBS with 0.01% 
Tween 20 (PBS-T) to remove soluble components followed by incuba-
tion with rabbit anti-RhoU antibody (Abcam) for 1 h at RT. The arrays 
were washed three times in PBS-T and then incubated with Alexa Fluor 
647–labeled anti–rabbit H+L.  Subsequently, the arrays were washed 
four more times with PBS-T and four times with water before being 
centrifugally dried (1,000 rpm for 5 min at RT). Finally, the arrays were 
scanned using a GenePix 4100A Microarray Scanner (Molecular De-
vices) using the 635-nm channel.
Protein microarray data analysis
Microarray images were gridded and quantitated using GenePix Pro 
software (version 7; Molecular Devices). Median intensities (features 
and local backgrounds) were used. Intensity values (feature minus 
background) from the RhoU-treated and control arrays were used to 
calculate MO = log2(RhoU/control) and A = log2(sqrt[RhoU*control]) 
values. These values were then Lowess transformed to normalize in-
tensity between arrays and remove technical sources of error (print tip 
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and location), resulting in the final estimate of magnitude change (ML). 
Duplicate features (representing identical protein) were used to calcu-
late the average (Avg ML) and standard deviation. A t test (paired two 
tailed) was used to assess the statistical significance (p-value) of each 
estimate (under the null hypothesis that Avg ML = 0). A threshold of 
95% confidence (P < 0.05) was used to filter data.
Statistical analyses
Datasets were compared using two-tailed t tests (unless otherwise 
stated in the figure legend) and presented as mean ± SEM. Statistical 
significance was accepted for P ≤ 0.05.
Online supplemental material
Fig. S1 shows the effect of PAK4 knockdown on MCF-7 cellular 
adhesion and random migration and confirms that depletion of 
PAK4 reduces RhoU levels in breast cancer cells. This figure also 
demonstrates that neither PAK1 nor PAK2 knockdown alters focal 
adhesion dynamics in MDA-MB-231 cells. Fig. S2 shows that PAK4 
can interact with paxillin, vinculin, and RhoV. This figure also shows 
that RhoU can interact with both PAK1 and PAK4 and that these 
interactions are through different binding sites. Additionally, this figure 
highlights that RhoU levels can be regulated by PAK4 and Sharpin 
overexpression. Fig. S3 shows that RhoU effector loop mutants that still 
bind PAK4 can rescue the adhesion phenotype of a PAK4 knockdown 
background. This figure also demonstrates that RhoU is localized in 
focal adhesions of MDA-MB-231 cells and that levels of paxillin S272 
are affected after PAK4, but not PAK1, knockdown. Table S1 lists 
the RhoU-interacting proteins identified from the protein microarray. 
Online supplemental material is available at http ://www .jcb .org /cgi /
content /full /jcb .201501072 /DC1.
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